Senate Bill 844 (SB 844)

---

Beginning July 1, 2026, Florida will implement a significant advancement in healthcare education and sickle cell disease advocacy through Senate Bill 844 (SB 844). The legislation strengthens continuing education requirements for healthcare professionals who prescribe controlled substances by mandating specialized training on the evidence-based management of pain associated with sickle cell disease.

This landmark legislation represents an important step toward improving healthcare experiences for individuals living with sickle cell disease and addressing longstanding disparities in pain treatment.

Why This Law Matters

Sickle cell disease (SCD) is an inherited blood disorder that affects approximately 100,000 Americans and disproportionately impacts individuals of African descent. Severe pain episodes, often referred to as vaso-occlusive crises, are among the most common and debilitating complications of the disease.

For decades, many individuals with sickle cell disease have reported challenges when seeking treatment for pain, including:

• Delays in receiving care
• Misunderstanding of disease-related pain
• Bias and stigma in healthcare settings
• Barriers to accessing appropriate pain management
• Inconsistent adherence to evidence-based treatment guidelines

Senate Bill 844 seeks to address these concerns by ensuring healthcare providers receive updated education on best practices for treating sickle cell pain and delivering culturally responsive care.

Key Provisions of Senate Bill 844

Who Must Complete the Training?

The law applies to healthcare practitioners who:

• Hold a Florida professional license, and
• Are registered with the U.S. Drug Enforcement Administration (DEA) to prescribe controlled substances.

This includes, but is not limited to:

• Physicians
• Physician Assistants (PAs)
• Advanced Practice Registered Nurses (APRNs)

What Is Required?

Florida already requires certain prescribers to complete a two-hour continuing education course on controlled substance prescribing as part of license renewal.

Under Senate Bill 844, that course must now include specific instruction on:

• Evidence-based treatment protocols for sickle cell pain
• Appropriate pain assessment and management strategies
• Reducing barriers to care for individuals living with sickle cell disease
• Addressing healthcare disparities and bias
• Delivering culturally responsive and patient-centered care

Enforcement and Compliance

Healthcare professionals must complete the required continuing education as part of their license renewal process.

Failure to satisfy the educational requirements may result in disciplinary action by the practitioner’s respective professional licensing board.

Expected Impact on the Sickle Cell Community

The passage of Senate Bill 844 is expected to:

Improve Patient Outcomes

Better-informed healthcare providers can make more timely and appropriate treatment decisions during sickle cell pain crises.

Reduce Stigma

The law recognizes that individuals with sickle cell disease have historically faced skepticism regarding their pain experiences and encourages evidence-based, compassionate care.

Increase Healthcare Equity

By focusing on culturally responsive care and reducing barriers to treatment, the legislation supports more equitable healthcare experiences for patients living with sickle cell disease.

Strengthen Provider Education

Enhanced training helps ensure healthcare professionals remain informed about current clinical guidelines and best practices.

A Step Forward for Florida

Senate Bill 844 reflects growing recognition of the unique challenges faced by individuals and families affected by sickle cell disease. By strengthening provider education and emphasizing evidence-based pain management, Florida is taking an important step toward improving healthcare access, patient experiences, and quality of care.

At Crescent Moon Cellubration, Inc., we celebrate this advancement and remain committed to supporting warriors, families, caregivers, and advocates through education, resources, awareness, and community engagement.

For additional information about sickle cell disease, advocacy efforts, and community resources, connect with Crescent Moon Cellubration, Inc.

Sources

1. Florida Senate Bill 844 – Florida Legislature, Senate Bill 844 (2026), relating to continuing education requirements for healthcare practitioners treating sickle cell disease.
2. Florida Legislature, Official Senate Bill Text and Legislative Analysis.
3. Centers for Disease Control and Prevention – Sickle Cell Disease Overview and Public Health Information.
4. National Heart, Lung, and Blood Institute – Evidence-Based Guidelines for the Management of Sickle Cell Disease.

This article is provided for educational and informational purposes only and should not be construed as legal or medical advice. Individuals should consult qualified healthcare professionals and refer to official Florida legislative resources for the most current information regarding Senate Bill 844 and related healthcare requirements.